Businesses – AstraZeneca
AstraZeneca plc is an Anglo–Swedish multinational pharmaceutical and biopharmaceutical company. In 2013, it moved its headquarters to Cambridge, UK, and concentrated its R&D in three sites: Cambridge; Gaithersburg, Maryland, USA (location of MedImmune) for work on biopharmaceuticals; and Mölndal (near Gothenburg) in Sweden, for research on traditional chemical drugs. AstraZeneca has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation. The company was founded in 1999 through the merger of the Swedish Astra AB and the English Zeneca Group (itself formed by the demerger of the pharmaceutical operations of Imperial Chemical Industries in 1993). Since the merger it has been among the world’s largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014). AstraZeneca has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. It has secondary listings on the New York Stock Exchange and the OMX exchange. open_in_new AstraZeneca on Wikipedia

lens Planning

AstraZeneca clearly publicly state which goals are priorities for the business: open_in_new Source

lens Commitments

AstraZeneca has public measurable environmental and/or social commitments in place to tackle issues that indirectly support the goals open_in_new Source

lens Actions

AstraZeneca give clear examples of how they support the goals through specific actions open_in_new Source

lens Progress

AstraZeneca publicly share their direct measurable contributions to specific goals open_in_new Source